articleBMC Medical GenomicsApr 24, 2009GOLD OA

PrognoScan: a new database for meta-analysis of the prognostic value of genes

Chugai Pharma (United States) · Kyushu Institute of Technology · +2 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Background

In cancer research, the association between a gene and clinical outcome suggests the underlying etiology of the disease and consequently can motivate further studies. The recent availability of published cancer microarray datasets with clinical annotation provides the opportunity for linking gene expression to prognosis. However, the data are not easy to access and analyze without an effective analysis platform. DESCRIPTION: To take advantage of public resources in full, a database named "PrognoScan" has been developed. This is 1) a large collection of publicly available cancer microarray datasets with clinical annotation, as well as 2) a tool for assessing the biological relationship between gene expression and prognosis. PrognoScan employs the minimum P-value approach for grouping patients for survival analysis that finds the optimal cutpoint in continuous gene expression measurement without prior biological knowledge or assumption and, as a result, enables systematic meta-analysis of multiple datasets.

Conclusion

PrognoScan provides a powerful platform for evaluating potential tumor markers and therapeutic targets and would accelerate cancer research. The database is publicly accessible at http://gibk21.bse.kyutech.ac.jp/PrognoScan/index.html.

Citation impact

1,069
total citations
FWCI
1.23
Percentile
100%
References
62
Citations per year

Authors

4

Topics & keywords

Keywords
  • Annotation
  • DNA microarray
  • Microarray databases
  • Meta-analysis
  • Microarray analysis techniques
  • Microarray
  • Human genetics
  • Bioinformatics
UN Sustainable Development Goals
  • Partnerships for the goals
No related works found for this paper.

Funding